公开(公告)号：US20160152603A1

公开(公告)日：2016-06-02

申请号：US15013625

申请日：2016-02-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: C07D405/04

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20160152598A1

公开(公告)日：2016-06-02

申请号：US15013675

申请日：2016-02-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: C07D401/06

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20150307497A1

公开(公告)日：2015-10-29

申请号：US14443598

申请日：2013-11-18

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Shinkichi SUZUKI ,  Masami YAMADA ,  Makoto KAMATA ,  Takuto KOJIMA ,  Ikuo FUJIMORI ,  Kenichiro SHIMOKAWA

IPC: C07D487/04 ,  C07D405/14

CPC classification number: C07D487/04 ,  C07D209/46 ,  C07D401/06 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/14 ,  C07D519/00

Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa═ or —N═; X2 is —CRb═ or —N═; X3 is —CRc= or —N═; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.

Abstract translation: 提供具有胆碱能毒蕈碱M1受体阳性变构调节剂活性的化合物，可用作阿尔茨海默病，精神分裂症，疼痛，睡眠障碍等的预防或治疗药物。 本发明涉及由下式表示的化合物：其中环A是任选具有取代基的4-至7-元环; L是-O - ， - S - ， - SO-或-SO 2 - ; R1是任选具有取代基的C 1-6烷基（条件是当L是-O-，R 1不是被卤素原子任意取代的C 1-6烷基时）或任选具有取代基的环状基团 （s）; X1为-CRa =或-N =; X2为-CRb =或-N =; X3是-CRc =或-N=; R a，R b和R c各自为任选具有取代基的C 1-6烷基，C 2-6烯基，C 1-6烷氧基，C 3-6环烷基，C 3-6环烷氧基或C 6-14芳基， H或卤素，或其盐。